Vutiglabridin

Small molecule

Also known as HSG4112

Partialsignal

Evidence outlook · lead readout

NCT06329141 · Parkinson Disease

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

NCT06329141: The randomized, placebo-controlled Phase 2 trial in early Parkinson's disease randomized 99 participants. In the per-protocol analysis (77 participants), the 800 mg dose improved the MDS-UPDRS Part III score by 3.56 points against placebo (P = .03); the intention-to-treat result is not reported.

Caveat: result from a company announcement and a conference presentation, in the per-protocol population (77 of 99 randomized); not from the registry or a peer-reviewed publication.

Also in development:Osteoarthritis · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Osteoarthritis
Parkinson's Disease
Other / comorbidity
Phase 1 (4)
Other / comorbidity
NCT04703764 · Glaceum
2021-02-15 – 2022-02-03 · Obesity
What this study did
NCT04733001 · Glaceum
2020-07-12 – 2021-02-10 · Obesity
What this study did

Competitive landscape

This drug's own stage for Osteoarthritis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vutiglabridin: this drugPhase 2Small moleculeparaoxonase-2 (PON2)not yet gradedNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
AllocetraPhase 2Cell therapyMacrophage reprogrammingnot yet gradedNo reviewed efficacy summary in this indication
PLX-PAD
—(overall)
Cell therapyMesenchymal stem cells (immunomodulatory, pro-angiogenic)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.